Search

for
Search:

Research

5 / 1000+ results

research Expression Profile of CD10, BCL-2, p63, and EMA in the Normal Skin and Basal Cell Carcinomas: An Immunohistochemical Reappraisal

9 citations , May 2022 in “Actas Dermo-Sifiliográficas”

This study found that basal cell carcinoma exhibits altered expression patterns of CD10, p63, BCL-2, and EMA proteins compared to normal skin, with notable differences in staining and reactivity.

research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases

2 citations , May 2022 in “International Journal of Impotence Research”

This pharmacovigilance study found strong disproportionality signals suggesting an association between finasteride and Peyronie's disease-related clinical features, but the evidence does not confirm a causal link.

research EMACIATION WITH DUAL INFECTION OF MALASSEZIOSIS AND EHRLICHIOSIS IN DOMESTIC DOG

March 2026 in “Buletin Veteriner Udayana”

This case report describes a 4-month-old domestic dog suffering from emaciation alongside Malasseziosis and Ehrlichiosis, showing significant clinical improvement after treatment, including dietary changes, medicated bathing, antiparasitic, antibiotic therapy, and supportive care.

Hematopoiesis Revolves Around the Primordial Evolutionary Rhythm of Innate Immunity and Purinergic Signaling – A Journey to the Developmental Roots

research EMATOPOIESIS REVOLVES AROUND THE PRIMORDIALEVOLUTIONAL RHYTHM OF INNATE IMMUNITY AND PURINERGIC SIGNALING – A JOURNEY TO THE DEVELOPMENTAL ROOTS

January 2024 in “Wiadomości Lekarskie”

This study highlights the role of innate immunity and purinergic signaling in regulating hematopoiesis and hematopoietic stem/progenitor cell specification. The researchers observed that these ancient pathways operate both paracrinally and autocrinally within HSPCs, maintaining their developmental function throughout evolution.

research EFLÚVIO TELÓGENO ASSOCIADO AO USO DE MEDICAMENTOS EMAGRECEDORES: MECANISMOS FISIOPATOLÓGICOS E EVIDÊNCIAS CLÍNICAS

August 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação”

This narrative review suggests that the association between weight-loss medications and telogen effluvium is primarily due to metabolic changes from rapid weight loss, rather than a direct pharmacological effect on hair follicles.

View more "ema" in research →

Community Join

5 / 223 results

community EMA is re-examining Winlevi (clascoterone at lower concentration)

8 upvotes 1 year ago

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

community EMAs Response to my Mail i sent them explaining the importance of Finasteride for hairloss in EU

51 upvotes 1 year ago

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

community Just Like France Belgium disagrees with EMA and will veto against Finasteride

in Finasteride/Dutasteride 54 upvotes 1 year ago

Belgium disagrees with the EMA and does not authorize the 1 mg oral form of finasteride for androgenic alopecia, citing a negative benefit-risk ratio. Despite this, some individuals in Belgium can still obtain finasteride through prescriptions, and there is debate over its mental health risks versus its benefits for hair loss and other health issues.

community European Medecine Agency (EMA) review of Finasteride and Dutasteride

in Finasteride/Dutasteride 37 upvotes 1 year ago

Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.

community Bryan Johnson's email regarding hair loss and his protocol (including why he doesn't take Fin or Dut).

in Research/Science 6 upvotes 5 months ago

Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.

View more "ema" in community →

Experts

6 / 8 results

All 8 expert results →

Clinics

6 / 7 results

All 7 clinic results →

Learn

— no results

Try a deeper search in learn →